Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management

American Journal of Hematology

Volumn 88, Issue 2, 2013, Pages 141-150

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; CYTOKINE; FLUOXYMESTERONE; GANDOTINIB; GIVINOSTAT; HYDROXYUREA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 8; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; LENALIDOMIDE; LESTAURTINIB; LNK PROTEIN; MEMBRANE PROTEIN; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PACRITINIB; PANOBINOSTAT; POMALIDOMIDE; PREDNISOLONE; PREDNISONE; RUXOLITINIB; SRSF2 PROTEIN; TESTOSTERONE ENANTATE; TET2 PROTEIN; THALIDOMIDE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; XL 019;

ABDOMINAL DISCOMFORT; ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BASOPHILIA; BONE MARROW SUPPRESSION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME 7; CHROMOSOME 7Q; CHROMOSOME 8; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ASSESSMENT TOOL; CREATININE BLOOD LEVEL; CYTOGENETICS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; DRUG SAFETY; DYNAMIC INTERNATIONAL PROGNOSTIC SCORING SYSTEM PLUS; ERYTHROCYTE TRANSFUSION; EXON; FATIGUE; GENE INSERTION; GENE LOCATION; GENE MUTATION; HUMAN; KARYOTYPE; LEUKEMIA; LEUKOCYTE COUNT; LIGHT CHAIN; LIVER TOXICITY; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOMA CELL; NAUSEA; NIGHT SWEAT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RISK; RISK ASSESSMENT; RISK STRATIFICATION; SIDE EFFECT; SKIN ULCER; SPLENOMEGALY; STEM CELL; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ANTINEOPLASTIC AGENTS; BONE MARROW; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; HUMANS; JANUS KINASE 2; MUTATION; PRIMARY MYELOFIBROSIS; PROGNOSIS; RADIOTHERAPY; RECEPTORS, THROMBOPOIETIN; REPRESSOR PROTEINS; SPLENECTOMY; STEM CELL TRANSPLANTATION;

EID: 84872970465     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23384     Document Type: Article

References (93)

1. Thompson AR, Forrey AW, Gentry PA, et al. Human factor IX in animals: Kinetics from isolated, radiolabelled protein and platelet destruction following crude concentrate infusions. Br J Haematol 1980;45:329-342.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
3. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-1138.
4. Dormehl IC, Kilian JG, Maree M, Jacobs L. Investigation by scintigraphic methods of platelet kinetics under normal and septic shock conditions in the experimental baboon model. Am J Physiol Imaging 1990;5:75-79.
5. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011;25:1200-1202.
6. Saitta A, Coglitore G, De Leo A, et al. Platelet aggregation and blood catecholamines in healthy young persons after the exercise test. Boll Soc Ital Cardiol 1980;25:347-354.
7. Bulian I, Pagnan A, Faggiotto A, Visona A. Evaluation of the platelet aggregation test carried out by the method of pressure filtration of the platelet aggregates (PFAP) in a group of healthy male subjects. Ric Clin Lab 1980;10 (Suppl 2):27-33.
8. Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med 2011;364:488-490.
9. Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: Significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012;120:4168-4171.
10. Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-1963.
11. Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010;363:1189-1190.
12. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:8520-8530.
13. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356-1363.
14. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265.
15. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 2005;105:973-977.
16. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097.
17. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: Aconsensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-438.
18. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132.
19. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979;43:185-190.
20. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: The 2008 WHO classification. Am J Hematol 2010;85:62-69.
21. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: Literature review and discussion. Eur J Haematol 2009;82:329-338.
22. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol 2011;29:3179-3184.
23. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: A distinct entity? Leuk Res 2001;25:829-838.
24. Orazi A, O'Malley DP, Jiang J, et al. Acute panmyelosis with myelofibrosis: An entity distinct from acute megakaryoblastic leukemia. Mod Pathol 2005;18:603-614.
25. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-2901.
26. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-1708.
27. Hussein K, Pardanani AD, Van Dyke DL, et al. International Prognostic Scoring System-Independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010;115:496-499.
28. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia 2011;25:82-88.
29. Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype. Am J Hematol 2009;85:14-17.
30. Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of International Prognostic Scoring System and Dynamic International Prognostic Scoring System. Haematologica, in press.
31. Patnaik MM, Caramazza D, Gangat N, et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol, in press.
32. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-397.
33. Gangat N, Caramazza D, Vaidya R, et al. DIPSS-Plus: A refined Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J Clin Oncol, in press.
34. Eriksson KA, Sigvaldason A, Lindholm A, et al. Platelet activation in response to phlebotomy. An experimental study of healthy blood donors. Acta Med Scand 1982;212:121-123.
35. Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: Nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010;24:105-109.
36. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008;22:756-761.
37. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114:1477-1483.
38. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24:1302-1309.
39. Renard DC, Bolton MM, Rhee SG, et al. Modified kinetics of platelet-derived growth factor-induced Ca2+ increases in NIH-3T3 cells overexpressing phospholipase C gamma 1. Biochem J 1992;281 (Part 3):775-784.
40. Baluda VP, Kirichuk VF, Kolesnikova LM, Chekalina SI. Changes in platelet aggregation and fibrinolytic activity of blood in healthy persons during the 23-day physical cycle. Biull Eksp Biol Med 1979;87:478-480.
41. Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012;51:743-755.
42. Ludlam CA. Evidence for the platelet specificity of beta-thromboglobulin and studies on its plasma concentration in healthy individuals. Br J Haematol 1979;41:271-278.
43. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-911.
44. Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol 2012;30:1087-1094.
45. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356-1363.
46. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol 2009;27:5587-5593.
47. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008;112:2726-2732.
48. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010;116:2857-2858.
49. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010;16:358-367.
50. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J 2007;13:377-383.
51. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002;117:288-296.
52. Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006;106:1974-1984.
53. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-2541.
54. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158-1164.
55. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009;27:4760-4766.
56. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009;83:154-155.
57. Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5)(q31)-associatedmyelofibrosis: Cytogenetic and JAK2V617F molecular remissions. Leukemia 2007;21:1827-1828.
58. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients. Ann Hematol, in press.
59. Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alpha therapy in myelofibrosis with myeloid metaplasia. Blood 2001;97:1896.
60. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant, in press.
61. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: A prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009;114:5264-5270.
62. Effiong CE, Usanga EA, Mellits ED. Platelet count in healthy full-term Nigerian neonates. Trop Geogr Med 1976;28:329-332.
63. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials. Leukemia 2008;22:23-30.
64. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27:4563-4569.
65. Verstovsek S, Kantarjian H, Mesa RA, et al. Long-term follow up and optimized dosing regimen of INCB018424 in patients with myelofibrosis: Durable clinical, functional and symptomatic responses with improved hematological safety. ASH Annual Meeting Abstracts 2009;114:756-
66. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. ASH Annual Meeting Abstracts 2009;114:311-
67. Pardanani AD, Gotlib JR, Jamieson C, et al. A phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: Clinical response is accompanied by significant reduction in JAK2V617F allele burden. ASH Annual Meeting Abstracts 2009;114:755-
68. Vannucchi AM, Guglielmelli P, Lupo L, et al. A phase 1/2 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: Final results. ASH Annual Meeting Abstracts 2010;116:314-
69. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150:446-455.
70. DeAngelo DJ, Spencer A, Fischer T, et al. Activity of oral panobinostat (LBH589) in patients with myelofibrosis. ASH Annual Meeting Abstracts 2009;114:2898-
71. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis with anemia. Leukemia, in press.
72. Mesa R, Pardanani AD, Hussein K, et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol, in press.
73. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-1127.
74. Tefferi A, Litzow M, Pardanani A. Long-term outcome of ruxolitinib therapy in myelofibrosis. N Engl J Med, in press.
75. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Eng J Med 2012;366:799-807.
76. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Eng J Med 2012;366:787-798.
77. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol, in press.
78. Santos FPS, Kantarjian HM, Jain N, et al. Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera/essential thrombocythemia myelofibrosis. Blood, in press.
79. Rafferty M, Walters MR, Dawson J. Anti-platelet therapy and aspirin resistance-Clinically and chemically relevant? Curr Med Chem 2010;17:4578-4586.
80. Mishchenko E, Tefferi A. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. Eur J Haematol, in press.
81. Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006;107:361-370.
82. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998;91:3630-3636.
83. Doki N, Irisawa H, Takada S, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Intern Med 2007;46:187-190.
84. Angermayr B, Cejna M, Schoder M, et al. Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood 2002;99:4246-4247.
85. Belohlavek J, Schwarz J, Jirasek A, et al. Idiopathic myelofibrosis complicated by portal hypertension treated with a transjugular intrahepatic portosystemic shunt (TIPS). Wien Klin Wochenschr 2001;113:208-211.
86. Tanaka N, Yamakado K, Kihira H, et al. Re: Transjugular intrahepatic portosystemic shunt for intractable esophageal-gastric variceal hemorrhage in a patient with idiopathic myelofibrosis. Cardiovasc Intervent Radiol 2000;23:491-492.
87. Alvarez-Larran A, Abraldes JG, Cervantes F, et al. Portal hypertension secondary to myelofibrosis: A study of three cases. Am J Gastroenterol 2005;100:2355-2358.
88. Wiest R, Strauch U, Wagner H, et al. A patient with myelofibrosis complicated by refractory ascites and portal hypertension: To tips or not to tips? A case report with discussion of the mechanism of ascites formation. Scand J Gastroenterol 2004;39:389-394.
89. Tefferi A, Mesa RA, Nagorney DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients. Blood 2000;95:2226-2233.
90. Feldman LS, Demyttenaere SV, Polyhronopoulos GN, Fried GM. Refining the selection criteria for laparoscopic versus open splenectomy for splenomegaly. J Laparoendosc Adv Surg Tech A 2008;18:13-19.
91. Iwase K, Higaki J, Mikata S, et al. Laparoscopically assisted splenectomy following preoperative splenic artery embolization using contour emboli for myelofibrosis with massive splenomegaly. Surg Laparosc Endosc Percutan Tech 1999;9:197-202.
92. Hiatt JR, Gomes AS, Machleder HI. Massive splenomegaly. Superior results with a combined endovascular and operative approach. Arch Surg 1990;125:1363-1367.
93. Hocking WG, Machleder HI, Golde DW. Splenic artery embolization prior to splenectomy in end-stage polycythemia vera. Am J Hematol 1980;8:123-127.